Contusion spinal cord injury (SCI) is a major medical and socio-economic problem globally. The incidence of SCI is highest among young adults due to motor vehicle accidents, military or sports injuries, and violence (Selvarajah et al., 2014). The elderly and children are also at risk due to falls and accidents. SCI causes neurodegeneration, with profound loss of locomotor and sensory functions (Siddiqui et al., 2015). Pain and depression are also prevalent in a majority of SCI patients. Expenses for severe SCI are high: initial hospitalization, rehabilitation, and most likely the continuing need for a caregiver and medical care. SCI survivors with less severe injuries usually face lower but still hefty medical bills. However, people ≥ 50 years old with severe SCI may face medical expenses of over \$1.8 million during their lifetimes. These injuries also affect spouses and family members, emotionally and financially, and most injuries jeopardize employment for those affected. In sum, SCI has a lifelong effect on many people; it represents a major challenge for successful health care management.

Other than critical care management and rehabilitation, no current Food and Drug Administration-approved drug therapy exists for traumatic SCI (Siddiqui et al., 2015). Several pharmacological therapies, including methylprednisolone, have been investigated in SCI, without therapeutic success. SCI is divided into two distinct phases (primary and secondary). The primary injury (immediately after SCI) is the physical damage caused by a traumatic event. It cannot be restored. Secondary spinal cord injury is a response to the initial physical insult and results from mechanistic crosstalk between several deleterious pathways: neuroinflammation, redox, and excitotoxicity (Siddiqui et al., 2015). Secondary injury is therefore amenable to reversal and treatment. Spinal cord contusion at thoracic or cervical levels shows similar molecular mechanisms and responds to similar treatment strategies. Functional deficits in rats after SCI are evaluated mainly by "Basso Beattie Bresnahan" locomotor rating scale. The Basso Beattie Bresnahan rating scale includes with a 21-point scale to measure hind limb function at various time points after injury. The scale assesses several different categories, including limb movement and tail position, as described in our publications (Chou et al., 2011; Khan et al., 2018).

A critical examination of SCI pathobiology, its signaling mechanisms, and results from our initial studies indicate a disturbed nitric oxide (NO) metabolome as shown in **[Figure 1](#F1){ref-type="fig"}**. Under physiological condition, nitric oxide synthase (NOS)-derived NO reacts with Glutathione in presence of oxygen and forms S-nitrosoglutathione (GSNO). After SCI (pathological condition), calcium dysregulation-induced excitotoxicity mechanisms are responsible for producing deleterious neuronal nitric oxide synthase (nNOS)-dependent peroxynitrite and activating calpain (**Figures [1](#F1){ref-type="fig"}** and **[2](#F2){ref-type="fig"}**). These mechanisms cause lesions, neurodegeneration, pain sensitivity and functional deficits following SCI (Chou et al., 2011; Khan et al., 2018). Our publications (Chou et al., 2011; Khan et al., 2016, 2018) in SCI/traumatic brain injury show that these deleterious mechanisms are effectively down regulated by GSNO (an endogenous component of the human brain/body), leading to neuroprotection, improved pain sensitivity and functional recovery after SCI (Chou et al., 2011; Khan et al., 2018) and traumatic brain injury (Khan et al., 2016). GSNO invokes its effect mainly *via* S-nitrosylation, a reversible secondary modification of cysteines, leading to altered activity of S-nitrosylated enzymes such as NOS, calpains, nuclear factor-kappa B, hypoxia-inducible factor 1α, signal transducer and activator of transcription 3, and others. The degree of S-nitrosylation is reduced in many of neurodegenerative diseases due to increased peroxynitrite formation and thus decreased bioavailability of NO for GSNO biosynthesis.

![Schematic showing metabolism of NOS-derived NO under physiological *vs*. pathological condition.\
NOS-derived NO slowly reacts with GSH in presence of oxygen and forms GSNO under physiological condition. GSNO invokes its signaling *via* the mechanism of S-nitrosylation (adding NO moiety to sulfhydryl group) of proteins/enzymes in a regulated fashion. In contrast, in oxidative (pathological) environment, NO instantaneously reacts with superoxide forming peroxynitrite. Peroxynitrite, *via* nitration of tyrosine residue, forms 3-nitrotyrosine adduct of proteins/enzymes thus altering their functions. Peroxynitrite also oxidizes cysteine residue of proteins/enzymes rendering them inactive. NOS: Nitric oxide synthase; NO: nitric oxide; O~2~^--^ : superoxide; GSH: glutathione; GSNO: S-nitrosoglutathione; GSSG: oxidized glutathione; NH~3~: ammonia; GSNOR: S-nitrosoglutathione reductase; P-S-H: cysteine-protein; P-S-NO: S-nitrosoprotein; ONOO^--^: peroxynitrite; P-Tyr: tyrosine-protein; P-Tyr-NO~2~: nitrated-tyrosine protein; P-S(O)n-H: oxidized protein (where *n* represents number of oxygen atom ranging from 1 to 3).](NRR-14-973-g001){#F1}

![Schematic showing events involved in nNOS/peroxynitrite/calpain system *vs*. GSNO-mediated mechanisms under SCI.\
NO released from nNOS mediates physiological signaling events by reacting with GSH to generate GSNO. nNOS activation is mediated by NMDAR-induced Ca^2+^ influx and activation *via* phosphorylation of Serine^1412^, and denitrosylation of cysteine^331^. SCI induces sustained Ca^2+^ influx, activation of NMDAR, and dysregulation of nNOS. Consequent increase in superoxide (O~2~ ^--^) and depletion of GSH result in decreased GSNO biosynthesis and increased peroxynitrite formation, thus causing a sustained and prolonged activation of nNOS and calpains, leading to sustained nitro-oxidative stress, neurodegeneration, pain pathology and functional deficits. This deleterious nNOS/peroxynitrite/calpain system is down regulated by exogenously-treated or endogenously-produced (inhibiting GSNOR by N6022) GSNO *via* S-nitrosylation of specific cysteines of nNOS and calpains, leading to neuroprotection, improved pain sensitivity and optimal functional recovery. While arrows indicate increasing the activity, expression or levels, horizontal (cross) lines indicate inhibiting or decreasing the activity, expression or levels. NO: Nitric oxide; nNOS: neuronal nitric oxide synthase; GSH: glutathione; GSNO: S-nitrosoglutathione; NMDAR: N-methyl-D-aspartate receptor; Ca^2+^: calcium ion; SCI: spinal cord injury; O~2~^--^: superoxide; GSNOR: S-nitrosoglutathione reductase; -SNO: S-nitroso; N6022: GSNO reductase inhibitor( 3-(5-(4-(1H-imidazol-1-yl) phenyl)-1-(4-carbamoyl-2-methylphenyl)-1H-pyrrol-2-yl) propanoic acid)); NR1: Anti-NMDA Receptor 1; NR2: Anti-NMDA Receptor 2; PSD-95: postsynaptic density 95; 3-NT: 3-nitrotyrosine.](NRR-14-973-g002){#F2}

Increased levels of neuronal peroxynitrite are involved in SCI secondary injury, causing nitro-oxidative stress and neuronal cell death (Bao and Liu, 2003). Peroxynitrite is formed by a diffusion limited reaction between NO and superoxide when they are simultaneously and instantaneously produced in the same compartment by aberrant nNOS activity. Interestingly, peroxynitrite is also responsible for the aberrant activity of nNOS because peroxynitrite oxidizes cysteines of the zinc thiolate cluster of NOS. Peroxynitrite also oxidizes and depletes tetrahydrobiopterin, a cofactor required for NOS activity, which also contributes to the aberrant activity and uncoupling of nNOS. Furthermore, Peroxynitrite causes a sustained activation of calpains *via* 3-nitrotyrosine (3-NT) formation (Khan et al., 2016), leading to neurodegeneration and functional deficits (Khan et al., 2011, 2016). In SCI, the observed increased levels of 3-NT, a peroxynitrite adduct of tyrosine residue, suggest its pathological role in SCI (Khan et al., 2018). Inhibition of nNOS activity following SCI has been shown to provide some degree of neuroprotection, and nNOS KO mice show improved recovery after SCI (Farooque et al., 2001), indicating a deleterious role of nNOS activity in SCI and that nNOS-based therapy for SCI is a logical approach.

Furthermore, 3-NT positive neurons are more sensitive to increased calpain activity and neuronal cell death (Rameau et al., 2003). Increased calpain activity was indicated by specific SBDP145 kDa alpha II spectrin degradation product, without changes in expression levels of either calpains in SCI. These results indicate that increased peroxynitrite enhances calpain activity. As with GSNO, calpain inhibitors inhibit calpain activity. However, calpain inhibitors had no effect on the activation of nNOS and the production of peroxynitrite, supporting our hypothesis that GSNO invokes its effects *via* the inhibition of both nNOS and calpain, thus decreasing peroxynitrite, reducing neurodegeneration and showing greater and accelerated efficacy. Reversible down regulation of nNOS as well as calpain activity, such as *via* GSNO/S-nitrosylation, is preferred because it maintains the required physiological activity of calpains/nNOS. The pathological roles of other NOS enzymes (inducible and endothelial) in contusion SCI's neurodegeneration and pain are not well understood.

In addition to GSNO's anti-neurodegenerative, anti-inflammatory and anti-oxidant effects, it also protects against endothelial dysfunction and increases vessel density *via* angiogenesis (Khan et al., 2015). In clinical settings of SCI, GSNO is of great relevance due to its vasodilatory, cerebral blood flow-enhancing and blood-brain barrier-protecting activities (Khan et al., 2011). However, the mechanism of GSNO's effect on pain is not clearly understood because the mechanisms underlying neuropathic pain are multifactorial and complex. Among them, peroxynitrite originating from N-Methyl-D-aspartic acid receptor activation and NOS activity (Tanabe et al., 2009) are prominent causes of neuropathic pain following nerve injury. N-Methyl-D-aspartic acid receptor activation and calcium dysregulation are also associated with nNOS activation and peroxynitrite formation in SCI.

Recently, the mechanism of S-nitrosylation/GSNO has been reported to reduce pain sensitivity (Shunmugavel et al., 2012). Therefore, S-nitrosylation/GSNO-mediated inhibition of peroxynitrite production, leading to reduced neurodegeneration and demyelination, may be responsible for alle*via*ting pain sensitivity. GSNO is a natural component of the human body, and its exogenous increase by administration or by inhibiting GSNO reductase is not known to be associated with any adverse effects. GSNO reductase is the major GSNO-degrading enzyme and thus GSNO reductase KO mice store GSNO in excess.

Conclusively, GSNO blocked the production of peroxynitrite by inhibiting aberrant nNOS activity, reduced calpain activity, improved locomotor rating scale (Basso Beattie Bresnahan), and mitigated mechanical allodynia (**[Figure 2](#F2){ref-type="fig"}**). These findings support the efficacy of GSNO in ameliorating SCI and provide a rationale to evaluate GSNO-mediated signaling events in SCI. Furthermore, the therapeutic efficacy of GSNO may be amenable to manipulation by exogenous *vs.* endogenous (using N6022) and single dose *vs.* multiple doses. GSNO also shows similar efficacy in an animal model of lumbar spinal stenosis/compression (Shunmugavel et al., 2012), supporting its therapeutic potential for SCI therapy. Due to its translational potential, clinical relevance, and non-toxic nature, testing the efficacy of low dose GSNO may lead to human SCI therapy.
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